Filtered By:
Infectious Disease: Outbreaks
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 533 results found since Jan 2013.
Effectiveness of Coronavirus Vaccines against Syndrome Coronavirus 2 (SARS-CoV-2) and Its New Variants
Iran J Allergy Asthma Immunol. 2021 Dec 8;20(6):647-671. doi: 10.18502/ijaai.v20i6.8016.ABSTRACTThe widespread outbreak of coronavirus disease 2019 in late 2019 caused many people worldwide to die or suffer from certain clinical complications even after the recovery. The virus has many social and economic adverse effects. Studies on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have specified that spike, surface glycoprotein antigen, is considered as a major target to stimulate the immune system. This glycoprotein binds to the angiotensin-converting enzyme 2 on the surface of human cells especially lung epit...
Source: Iranian Journal of Allergy, Asthma and Immunology - December 18, 2021 Category: Allergy & Immunology Authors: Afshin Abdi Ghavidel Mahbubeh Rojhannezhad Bahram Kazemi Mojgan Bandehpour Source Type: research
Allergy and COVID-19
Acta Biomed. 2021 Nov 29;92(S7):e2021522. doi: 10.23750/abm.v92iS7.12402.ABSTRACTThe first cases of as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported in Wuhan, China in December 2019. The World Health Organization declared the global pandemic in March 2020. Coronavirus disease 2019 (COVID-19) showed high rates of mortality in the adult population, whereas a mild course was observed in childhood. Allergic diseases, characterized by a type-2 polarization of the immune system, were considered one of the major risk factor of severe COVID-19. Large amounts of clinical data and expert o...
Source: Acta Bio-Medica : Atenei Parmensis - November 29, 2021 Category: General Medicine Authors: Maria De Filippo Martina Votto Ilaria Brambilla Riccardo Castagnoli Lorenza Montagna Carlo Caffarelli Fabio Cardinale Michele Miraglia Del Giudice Mariangela Tosca Silvia Caimmi Amelia Licari Gian Luigi Marseglia Source Type: research
Statement on Data Published in PLOS Medicine on Tolerability and Immune Response of Johnson & Johnson Ebola Vaccine Regimen in Adults Living with HIV
NEW BRUNSWICK, N.J., October 29, 2021 – Data published in PLOS Medicine demonstrated that the Johnson & Johnson (the Company) Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), was well tolerated and induced a robust immune response in both healthy adults and adults living with HIV. These findings, alongside Phase 3 data recently published in The Lancet Infectious Diseases, support the potential prophylactic use of the vaccine regimen to protect people at risk of acquiring Ebola. The regimen was granted Marketing Authorisation by the European Commission in July 2020 and Prequalification from th...
Source: Johnson and Johnson - October 29, 2021 Category: Pharmaceuticals Source Type: news
